Metis Global Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.51M | Sell |
4,637
-929
| -17% | -$303K | 0.04% | 371 |
|
|
2025
Q1 | $1.5M | Buy |
5,566
+839
| +18% | +$227K | 0.04% | 371 |
|
|
2024
Q4 | $1.11M | Buy |
4,727
+347
| +8% | +$81.7K | 0.03% | 413 |
|
|
2024
Q3 | $1.2M | Buy |
4,380
+1,405
| +47% | +$386K | 0.04% | 404 |
|
|
2024
Q2 | $723K | Buy |
2,975
+35
| +1% | +$8.51K | 0.02% | 470 |
|
|
2024
Q1 | $439K | Sell |
2,940
-1,442
| -33% | -$216K | 0.02% | 585 |
|
|
2023
Q4 | $839K | Buy |
4,382
+94
| +2% | +$18K | 0.03% | 436 |
|
|
2023
Q3 | $759K | Buy |
4,288
+342
| +9% | +$60.6K | 0.04% | 440 |
|
|
2023
Q2 | $750K | Buy |
3,946
+300
| +8% | +$57K | 0.04% | 426 |
|
|
2023
Q1 | $730K | Buy |
3,646
+1,144
| +46% | +$229K | 0.05% | 400 |
|
|
2022
Q4 | $595K | Buy |
2,502
+1,157
| +86% | +$275K | 0.05% | 388 |
|
|
2022
Q3 | $269K | Buy |
+1,345
| New | +$269K | 0.04% | 445 |
|